Telmisartan is effective to ameliorate metabolic syndrome in rat model - a preclinical report

doi:10.2147/DMSO.S187092

CNU IR > Pharmacy and Science > Dept. of Pharmacy > Periodical Articles > Item 310902800/32180

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/32180

題名:	Telmisartan is effective to ameliorate metabolic syndrome in rat model - a preclinical report
作者:	Chen, Kai-Chun Li, Yingxiao Chang, Wei-Ting Kuo, Feng Yu Chen, Zhih-Cherng Cheng, Juei-Tang
貢獻者:	Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Psychosomat Internal Med Chi Mei Med Ctr, Dept Med Res Chi Mei Med Ctr, Dept Cardiol Kaohsiung Vet Gen Hosp, Cardiovasc Ctr Chia Nan Univ Pharm & Sci, Dept Pharm Chang Jung Christian Univ
關鍵詞:	metabolic syndrome telmisartan PPAR delta GSK0660 diet
日期:	2018
上傳時間:	2019-11-15 15:43:59 (UTC+8)
出版者:	DOVE MEDICAL PRESS LTD
摘要:	Background: Metabolic syndrome (MS) is known to be associated with hypertension, insulin resistance, and dyslipidemia, and it raises the risk for cardiovascular diseases and diabetes mellitus. Telmisartan is used in clinic as an angiotensin II receptor blocker and it is also identified as activating peroxisome proliferator-activated receptors delta (PPAR delta). Activation of PPAR delta produced beneficial effects on fatty acid metabolism and glucose metabolism. This study aims to investigate the effects of telmisartan on the modulation of MS in rats fed a high-fat/high-sodium diet. Methods: Rats were fed with a high-fat/high-sodium diet and received injections of streptozotocin at low dose to induce MS. Then, rats with MS were treated with telmisartan. The weight, glucose tolerance, and insulin sensitivity were measured. The lipid profiles were also obtained. The weights of retroperitoneal and epididymal fat pads were determined. The role of PPR delta in telmisartan treatment was identified in rats pretreated with the specific antagonist GSK0660. Results: The results showed that telmisartan, but not losartan, significantly reduced plasma glucose and plasma insulin, and improved insulin resistance in rats with MS. Telmisartan also decreased blood pressure and lipids more significantly than losartan. Moreover, GSK0660 effectively reversed the effects of telmisartan in the MS rats. In the MS group, telmisartan activated PPAR delta to enhance the levels of phosphorylated GLUT4 in muscle or the expression of phosphoenolpyruvate carboxykinase (PIRPCK) in the liver, which was also abolished by GSK0660. Telmisartan is useful to ameliorate hypertension and insulin resistance in rats with MS. Telmisartan improves the insulin resistance through increased expression of GLUT4 and down-regulation of PEPCK via PPAR delta-dependent mechanisms. Conclusion: Telmisartan has been proven to ameliorate MS, particularly in the prediabetes state. Therefore, telmisartan is suitable to develop for the management of MS in clinics.
???metadata.dc.relation.uri???:	http://dx.doi.org/10.2147/DMSO.S187092
關聯:	International Journal of Chronic Obstructive Pulmonary Disease, v.11, pp.901-911
顯示於類別:	[Dept. of Pharmacy] Periodical Articles

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
10.2147-DMSO.S187092.pdf		1128Kb	Adobe PDF	336	檢視/開啟
index.html		0Kb	HTML	1388	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....